The ticagrelor market covers the drug ticagrelor which is an oral, reversible, P2Y12 platelet aggregation inhibitor. Ticagrelor helps to prevent platelets from clumping together and forming clots. It is mainly used for reducing thrombotic cardiovascular events such as heart attack or stroke in patients with acute coronary syndrome or history of myocardial infarction. Ticagrelor market provides a faster, stronger and more consistent platelet inhibition as compared to other antiplatelet drugs. It offers promising benefits for prevention of major adverse cardiovascular events.

The global ticagrelor market is estimated to be valued at US$ 1481.28 Mn in 2024 and is expected to exhibit a CAGR of 3.0% over the forecast period 2024 to 2031.

Key Takeaways

Key players operating in the Ticagrelor Market Size are Atlas Roofing Corporation, BASF SE, Johns Manville, Duro-Last, Inc., E. I. Du Pont De Nemours, Inc., Owens Corning, Sika AG, Standard Industries Inc., and The Dow Chemical Company. Key players are focusing on new product development and launches to strengthen their product portfolio. For instance, in 2023, Bristol Myers Squibb launched Ticagrelor 90 mg film-coated tablets for the treatment of coronary artery disease.

Growing burden of cardiovascular diseases across the globe is driving the demand for ticagrelor. Increasing obese and geriatric population prone to heart attacks, strokes and other cardiovascular complications is a major factor augmenting the market growth. According to World Health Organization, cardiovascular diseases account for over 17.9 million deaths globally every year.
The ticagrelor market is expanding globally with presence of key manufacturers in major markets. Manufacturers are focusing on emerging economies in Asia Pacific, Latin America and Middle East & Africa through new product approvals and partnerships with local pharmaceutical companies. This helps to cater to the unmet needs and improve access to ticagrelor therapy.

Get more insights on Ticagrelor Market